Francis E. Lotrich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Francis E. Lotrich has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Bruce G. Pollock
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA; †Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA; ‡Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA; and §Rotman Research Institute and the Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada
6 shared publicationsMordechai Rabinovitz
Division of Gastroenterology and Hepatology, University of Pittsburgh, Pittsburgh, Pennsylvania
5 shared publicationsBarry Sears
Inflammation Research Foundation, Marblehead, MA, United States
3 shared publicationsRobert E. Ferrell
Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania
3 shared publicationsRobert K. McNamara
Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, United States
3 shared publicationsBruce G Pollock
2 shared publications
Latest Publications
- 1 March 2016
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 106, 19-25
Polyunsaturated fatty acids moderate the effect of poor sleep on depression risk
- 1 March 2016
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 106, 19-25
Polyunsaturated fatty acids moderate the effect of poor sleep on depression risk
- 1 August 2015
- Published by Elsevier in Brain Research
- Vol. 1617, 113-125
Inflammatory cytokine-associated depression
- 1 August 2015
- Published by Elsevier in Brain Research
- Vol. 1617, 113-125
Inflammatory cytokine-associated depression
- 1 May 2015
- Published by Oxford University Press (OUP)
- p. 241-272
Psychiatric Presentations Associated with Organ Failure and Systemic Illness
- 1 May 2015
- Published by Oxford University Press (OUP)
- p. 241-272
Psychiatric Presentations Associated with Organ Failure and Systemic Illness
- 30 November 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (5) , 1482-1489
Fibromyalgia Symptoms and Cirrhosis
Background An association between fibromyalgia and hepatitis C virus (HCV) has been previously described. However, the relationship between nonalcoholic steatohepatitis (NASH) and fibromyalgia symptoms has not been assessed, though they share several risk factors. Aim We aimed to assess the factors associated with fibromyalgia symptoms across etiologies of liver disease. Methods Patients with cirrhosis due to HCV, NASH, or alcohol were recruited from an outpatient hepatology clinic and administered the Hospital Anxiety and Depression Score, Pittsburgh Sleep Quality Index, and the modified 2010 American College of Rheumatology Diagnostic Criteria for Fibromyalgia. Serum inflammatory markers were measured with standard luminex assays. Results Of 193 participants, 53 (27 %) met criteria for fibromyalgia. Fibromyalgia symptoms were significantly associated with etiology of liver disease (HCV: 35 %, NASH: 30 %, alcohol-related liver disease: 12 %, p < 0.01). Using logistic regression, mood symptoms (OR 1.14, 95 % CI 1.06, 1.22), sleep disturbance (OR 1.32, 95 % CI 1.16, 1.52), and etiology of liver disease (NASH vs. HCV not different, alcohol vs. HCV OR 0.19, 95 % CI 0.05, 0.63) were associated with fibromyalgia symptoms. If abdominal pain was included in the model, etiology became nonsignificant, indicating that it may be central sensitization due to abdominal pain in patients with chronic liver disease that explains fibromyalgia symptoms rather than the etiology of liver disease or inflammation. Conclusions Fibromyalgia symptoms were significantly associated with HCV and NASH cirrhosis and with psychiatric symptoms. Future work should focus on the underlying pathophysiology and management of widespread pain in patients with cirrhosis.
- 30 November 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (5) , 1482-1489
Fibromyalgia Symptoms and Cirrhosis
Background An association between fibromyalgia and hepatitis C virus (HCV) has been previously described. However, the relationship between nonalcoholic steatohepatitis (NASH) and fibromyalgia symptoms has not been assessed, though they share several risk factors. Aim We aimed to assess the factors associated with fibromyalgia symptoms across etiologies of liver disease. Methods Patients with cirrhosis due to HCV, NASH, or alcohol were recruited from an outpatient hepatology clinic and administered the Hospital Anxiety and Depression Score, Pittsburgh Sleep Quality Index, and the modified 2010 American College of Rheumatology Diagnostic Criteria for Fibromyalgia. Serum inflammatory markers were measured with standard luminex assays. Results Of 193 participants, 53 (27 %) met criteria for fibromyalgia. Fibromyalgia symptoms were significantly associated with etiology of liver disease (HCV: 35 %, NASH: 30 %, alcohol-related liver disease: 12 %, p < 0.01). Using logistic regression, mood symptoms (OR 1.14, 95 % CI 1.06, 1.22), sleep disturbance (OR 1.32, 95 % CI 1.16, 1.52), and etiology of liver disease (NASH vs. HCV not different, alcohol vs. HCV OR 0.19, 95 % CI 0.05, 0.63) were associated with fibromyalgia symptoms. If abdominal pain was included in the model, etiology became nonsignificant, indicating that it may be central sensitization due to abdominal pain in patients with chronic liver disease that explains fibromyalgia symptoms rather than the etiology of liver disease or inflammation. Conclusions Fibromyalgia symptoms were significantly associated with HCV and NASH cirrhosis and with psychiatric symptoms. Future work should focus on the underlying pathophysiology and management of widespread pain in patients with cirrhosis.
- 25 November 2013
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 29 (6) , 635-644
The relationship between interleukin‐1 receptor antagonist and cognitive function in older adults with bipolar disorder
Objective: Cognitive impairments are a feature of bipolar disorder (BD) and could be worsened by inflammatory cytokines. We determined whether (i) serum interleukin‐1 receptor antagonist (IL‐1RA) was increased in elderly BD subjects; (ii) whether IL‐1RA was associated with worse neurocognitive function; and (iii) whether IL‐1RA was associated with white matter integrity.Methods: Twenty‐one euthymic BD patients (65 +/− 9 years) with serum available for IL‐1RA measures by enzyme‐linked immunoassays were compared with 26 similarly aged control participants. Four factor analysis‐derived z‐scores and a global z‐score were obtained from a battery of 21 neurocognitive tests. Diffusion tensor images were used to obtain fractional anisotropy (FA), and an automated labeling pathway algorithm was used to obtain white matter hyperintensity burden.Results: Interleukin‐1 receptor antagonist was elevated in BD subjects compared with controls (439+/−326 pg/mL vs. 269+/−109 pg/mL; p = 0.004). Moreover, IL‐1RA was inversely correlated with three cognitive function factors and global cognition (r = −0.37; p = 0.01). IL‐1RA continued to correlate with global cognitive function even when covarying for either IL‐6 or brain‐derived neurotrophic factor. Although FA was lower in BD subjects (0.368 +/− 0.02 vs. 0.381 +/− 0.01; p = 0.02), IL‐1RA was not associated with FA or white matter hyperintensity burden.Conclusion: Elevated serum levels of IL‐1RA in BD subjects, even during euthymic states, were associated with worse cognitive function. This association was not explained by co‐occurring increases in IL‐6, by decreased brain‐derived neurotrophic factor, nor by measures of white matter integrity. These cross‐sectional findings support the possibility that the IL‐1 family may contribute to cognitive impairments in BD. Copyright © 2013 John Wiley & Sons, Ltd.
- 25 November 2013
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 29 (6) , 635-644
The relationship between interleukin‐1 receptor antagonist and cognitive function in older adults with bipolar disorder
Objective: Cognitive impairments are a feature of bipolar disorder (BD) and could be worsened by inflammatory cytokines. We determined whether (i) serum interleukin‐1 receptor antagonist (IL‐1RA) was increased in elderly BD subjects; (ii) whether IL‐1RA was associated with worse neurocognitive function; and (iii) whether IL‐1RA was associated with white matter integrity.Methods: Twenty‐one euthymic BD patients (65 +/− 9 years) with serum available for IL‐1RA measures by enzyme‐linked immunoassays were compared with 26 similarly aged control participants. Four factor analysis‐derived z‐scores and a global z‐score were obtained from a battery of 21 neurocognitive tests. Diffusion tensor images were used to obtain fractional anisotropy (FA), and an automated labeling pathway algorithm was used to obtain white matter hyperintensity burden.Results: Interleukin‐1 receptor antagonist was elevated in BD subjects compared with controls (439+/−326 pg/mL vs. 269+/−109 pg/mL; p = 0.004). Moreover, IL‐1RA was inversely correlated with three cognitive function factors and global cognition (r = −0.37; p = 0.01). IL‐1RA continued to correlate with global cognitive function even when covarying for either IL‐6 or brain‐derived neurotrophic factor. Although FA was lower in BD subjects (0.368 +/− 0.02 vs. 0.381 +/− 0.01; p = 0.02), IL‐1RA was not associated with FA or white matter hyperintensity burden.Conclusion: Elevated serum levels of IL‐1RA in BD subjects, even during euthymic states, were associated with worse cognitive function. This association was not explained by co‐occurring increases in IL‐6, by decreased brain‐derived neurotrophic factor, nor by measures of white matter integrity. These cross‐sectional findings support the possibility that the IL‐1 family may contribute to cognitive impairments in BD. Copyright © 2013 John Wiley & Sons, Ltd.
- 1 November 2013
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 75 (5) , 475-483
Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids
- 1 November 2013
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 75 (5) , 475-483
Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids
- 1 June 2013
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 170 (6) , 592-597
Psychiatric Clearance for Patients Started on Interferon-Alpha-Based Therapies
- 1 June 2013
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 170 (6) , 592-597
Psychiatric Clearance for Patients Started on Interferon-Alpha-Based Therapies
- 18 December 2012
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 38 (6) , 985-995
Brain-Derived Neurotrophic Factor Serum Levels and Genotype: Association with Depression during Interferon-α Treatment
Depression has been associated with inflammation, and inflammation may both influence and interact with growth factors such as brain-derived neurotrophic factor (BDNF). Both the functional Val66Met BDNF polymorphism (rs6265) and BDNF levels have been associated with depression. It is thus plausible that decreased BDNF could mediate and/or moderate cytokine-induced depression. We therefore prospectively employed the Beck Depression Inventory-II (BDI-II), the Hospital Anxiety and Depression Scale (HADS), and the Montgomery–Asberg Depression Rating Scale (MADRS) in 124 initially euthymic patients during treatment with interferon-alpha (IFN-α), assessing serum BDNF and rs6265. Using mixed-effect repeated measures, lower pretreatment BDNF was associated with higher depression symptoms during IFN-α treatment (F144,17.2=6.8; P1,83.0=5.0; P=0.03), it was only associated with increased MADRS scores (F4,8.9=20.3; Pα therapy further lowered BDNF serum levels (F4,37.7=5.0; P=0.003), but this decrease occurred regardless of depression development. The findings thus do not support the hypothesis that decreasing BDNF is the primary pathway by which IFN-α worsens depression. Nonetheless, the results support the hypothesis that BDNF levels influence resiliency against developing inflammatory cytokine-associated depression, and specifically to a subset of symptoms distinct from those influenced by 5-HTTLPR.
- 18 December 2012
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 38 (6) , 985-995
Brain-Derived Neurotrophic Factor Serum Levels and Genotype: Association with Depression during Interferon-α Treatment
Depression has been associated with inflammation, and inflammation may both influence and interact with growth factors such as brain-derived neurotrophic factor (BDNF). Both the functional Val66Met BDNF polymorphism (rs6265) and BDNF levels have been associated with depression. It is thus plausible that decreased BDNF could mediate and/or moderate cytokine-induced depression. We therefore prospectively employed the Beck Depression Inventory-II (BDI-II), the Hospital Anxiety and Depression Scale (HADS), and the Montgomery–Asberg Depression Rating Scale (MADRS) in 124 initially euthymic patients during treatment with interferon-alpha (IFN-α), assessing serum BDNF and rs6265. Using mixed-effect repeated measures, lower pretreatment BDNF was associated with higher depression symptoms during IFN-α treatment (F144,17.2=6.8; P1,83.0=5.0; P=0.03), it was only associated with increased MADRS scores (F4,8.9=20.3; Pα therapy further lowered BDNF serum levels (F4,37.7=5.0; P=0.003), but this decrease occurred regardless of depression development. The findings thus do not support the hypothesis that decreasing BDNF is the primary pathway by which IFN-α worsens depression. Nonetheless, the results support the hypothesis that BDNF levels influence resiliency against developing inflammatory cytokine-associated depression, and specifically to a subset of symptoms distinct from those influenced by 5-HTTLPR.
- 13 October 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 18 (36) , 5920-5935
Inflammatory Cytokines, Growth Factors, and Depression
There is a plausible role for cytokines, brain-derived neurotrophic factor (BDNF), and their interaction in major depressive disorder’s (MDD) etiology. This review includes (i) briefly defining cytokines, (ii) a discussion of theories for why they may affect brain function, (iii) cross-sectional associations between cytokines and MDD, (iv) the effect of antidepressants on cytokines, (v) the behavioral effects of cytokines administration to humans, (vi) the behavior effects of their administration to animal models, and (vii) potential neurochemical systems influenced by cytokines. The role of BDNF is then briefly examined, along with a review of several studies that have examined a Val/Met polymorphism in the BDNF gene. The bidirectional relationship between BDNF and cytokines is subsequently discussed. Potential ramifications for MDD treatment that are appraised include (i) use of cytokine biomarkers for identifying specific populations for targeted MDD therapy, (ii) the use of medications that directly antagonize the role of inflammatory cytokines, (iii) potential indirect modifiers of cytokine activity, and (iv) possible downstream intracellular second messenger targets.
- 13 October 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 18 (36) , 5920-5935
Inflammatory Cytokines, Growth Factors, and Depression
There is a plausible role for cytokines, brain-derived neurotrophic factor (BDNF), and their interaction in major depressive disorder’s (MDD) etiology. This review includes (i) briefly defining cytokines, (ii) a discussion of theories for why they may affect brain function, (iii) cross-sectional associations between cytokines and MDD, (iv) the effect of antidepressants on cytokines, (v) the behavioral effects of cytokines administration to humans, (vi) the behavior effects of their administration to animal models, and (vii) potential neurochemical systems influenced by cytokines. The role of BDNF is then briefly examined, along with a review of several studies that have examined a Val/Met polymorphism in the BDNF gene. The bidirectional relationship between BDNF and cytokines is subsequently discussed. Potential ramifications for MDD treatment that are appraised include (i) use of cytokine biomarkers for identifying specific populations for targeted MDD therapy, (ii) the use of medications that directly antagonize the role of inflammatory cytokines, (iii) potential indirect modifiers of cytokine activity, and (iv) possible downstream intracellular second messenger targets.